65岁以下成人Ross、TAVR与外科主动脉瓣置换的趋势与结局
该观察性队列研究利用加州和纽约2000—2025年出院数据,分析18—64岁患者中Ross、TAVR、机械瓣SAVR与生物瓣SAVR的使用趋势及6年结局。结果显示Ross使用率在2005年后回升,且较生物瓣SAVR和TAVR具有更低的6年死亡风险。
要点
- Ross在<65岁成人中使用率回升,6年死亡风险低于生物瓣SAVR和TAVR
- TAVR较生物瓣SAVR死亡、感染性心内膜炎及心衰住院风险更高
- Ross与机械瓣SAVR的再干预风险高于生物瓣SAVR,但TAVR再干预风险更低
核心结论
- 在<65岁成人中,Ross使用率上升且6年死亡率低于生物瓣SAVR或TAVR,支持更广泛考虑用于年轻患者。
研究设计与样本
- 观察性队列研究,使用加州和纽约2000—2025年出院数据,纳入18—64岁接受Ross、TAVR、机械瓣SAVR或生物瓣SAVR的患者。
- 采用多变量时间-事件模型评估6年死亡、心肌梗死、卒中、感染性心内膜炎、再干预和起搏器植入风险。
主要发现
- Ross使用率从2000年2.8%降至2005年0.9%,后回升至2022年2.8%;TAVR在2011年后快速扩张,机械瓣SAVR下降,生物瓣SAVR在2017年后趋于平稳。
- 各组早期死亡率均低,Ross术后尤为罕见。
- 与生物瓣SAVR相比,Ross与更低的调整6年死亡率(HR 0.42;95%CI 0.19-0.91)和卒中风险相关。
- Ross和机械瓣SAVR的孤立主动脉瓣再干预及主动脉和/或肺动脉瓣再干预风险高于生物瓣SAVR,但TAVR后仍较低。
- TAVR较生物瓣SAVR与更高的死亡率(HR 1.48;95%CI 1.07-2.05)、感染性心内膜炎和心衰住院相关;机械瓣SAVR生存与生物瓣SAVR相当(HR 0.96;95%CI 0.85-1.08),但感染性心内膜炎、心肌梗死、心衰和起搏器植入风险更高。
临床怎么用
- 对<65岁主动脉瓣病变患者,评估Ross时应权衡其较低的6年死亡与卒中风险及较高的再干预风险。
- 与年轻患者沟通时,TAVR需说明其较生物瓣SAVR更高的死亡、感染性心内膜炎和心衰住院风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Transcatheter aortic valve replacement (TAVR) use among patients aged <65 years has risen rapidly, coinciding with renewed interest in the Ross procedure for aortic stenosis. This observational cohort study evaluated temporal trends in Ross, TAVR, and surgical aortic valve replacement (SAVR) utilization and compared their 6-year outcomes in adults 18-64 years old. METHODS: We used California and New York discharge data (2000-2025) to identify patients undergoing Ross, TAVR, mechanical (SAVR-mech), or biological SAVR (SAVR-bio). Multivariable time-to-event models assessed the 6-year risks of death, myocardial infarction, stroke, infective endocarditis (IE), reintervention, and pacemaker implantation. RESULTS: Ross utilization declined from 2.8% in 2000 to 0.9% in 2005, then rebounded to 2.8% by 2022. TAVR expanded rapidly after 2011, while SAVR-mech declined and SAVR-bio plateaued after 2017. Early mortality was low across all groups, and notably rare after the Ross procedure. Compared with SAVR-bio, the Ross procedure was associated with lower adjusted 6-year mortality (hazard ratio [HR], 0.42; 95%CI, 0.19-0.91) and stroke risk. The risk of isolated aortic valve reintervention and aortic and/or pulmonary valve reintervention was higher after Ross and SAVR-mech than SAVR-bio but remained lower after TAVR. TAVR was associated with higher mortality (HR, 1.48; 95% CI, 1.07-2.05), infective endocarditis, and heart failure hospitalization compared with SAVR-bio. SAVR-mech demonstrated comparable survival to SAVR-bio (HR, 0.96; 95% CI, 0.85-1.08) but higher risks of infective endocarditis, myocardial infarction, heart failure, and pacemaker implantation. CONCLUSIONS: Ross use in adults aged <65 years is rising and confers lower 6-year mortality rates than SAVR-bio or TAVR, supporting broader consideration for younger patients.
引用
- Alabbadi S, Toyoda N, Itagaki S, et al. Trends in Utilization and Outcomes of Ross, Transcatheter, and Surgical Aortic Valve Replacement in Adults Younger Than 65 Years Old. Ann Thorac Surg. 2026. PMID: 41763382. doi:10.1016/j.athoracsur.2026.02.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。